Table 3.
Echocardiographic characteristics of the patients treated with anthracyclines and trastuzumab - Association with cardiotoxicity.
| ECHO | Variable* | Cardiotoxicity | P | |
|---|---|---|---|---|
| Sim | Não | |||
| n = 5 | n = 44 | |||
| Baseline ECHO | EF (%) | 64 ± 4.8 | 68.3 ± 7.7 | 0.120 |
| GLS (%) | -19.3 ± 1.2 | -20.5 ± 2.0 | 0.100 | |
| E/E' | 8.9 ± 2.5 | 7.9 ± 1.6 | 0.450 | |
| LV S (cm/s) | 7.8 ± 1.1 | 8.3 ± 1.1 | 0.380 | |
| RV S (cm/s) | 12.6 ± 2.1 | 12.9 ± 2.0 | 0.760 | |
| ECHO 3 months | EF (%) | 57.6 ± 12.3 | 67.2 ± 6.4 | 0.006 |
| EF Dif. 3 months (%) | 6.4 ± 16.2 | 1.1 ± 7.2 | 0.190 | |
| GLS (%) | -15.2 ± 2 | -19.6 ± 2.1 | 0.005 | |
| GLS Dif. 3 months (%) | 4.1 ± 1.6 | 0.8 ± 1.6 | 0.008 | |
| E/E' | 7.1 ± 1.6 | 8.6 ± 1.9 | 0.230 | |
| LV S (cm/s) | 8 ± 0.8 | 8.5 ± 1.6 | 0.600 | |
| RV S (cm/s) | 12.6 ± 2.2 | 12.9 ± 2.3 | 0.800 | |
| ECHO 6 months | EF (%) | 52 ± 5.1 | 67.4 ± 6.6 | 0.001 |
| EF Dif. 6 months (%) | 12 ± 5.2 | 0.9 ± 9.8 | 0.004 | |
| GLS (%) | -15.6 ± 1.1 | -19.4 ± 2 | < 0.001 | |
| GLS Dif. 6 months (%) | 3.7 ± 1.8 | 1 ± 1.6 | 0.026 | |
| E/E' | 9 | 8.2 ± 2.4 | 0.040 | |
| LV S (cm/s) | 6.3 ± 0.5 | 7.8 ± 1.4 | < 0.001 | |
| RV S (cm/s) | 11.8 ± 1.6 | 13 ± 2 | 0.200 | |
*
Means ± SD; ECHO: Echocardiography; EF: Ejection Fraction (Simpson's); EF Dif.: Ejection Fraction Difference; GLS Dif.: Global Longitudinal Strain Difference; E/E': Ratio between E and E' wave values on Doppler echocardiography; LV S: S wave of the left ventricle; RV S: S wave of the right ventricle. The echocardiographic variables were compared by using paired Student t test, p value ≤ 0.05.